Yun J J, Mason D P
Department of Thoracic and Cardiovascular Surgery, Cleveland Clinic, Cleveland, OH, USA.
Minerva Chir. 2009 Feb;64(1):37-44.
Lung transplantation (LTx) is an established therapy for end-stage lung disease (ESLD). Survival after LTx is limited by infection and rejection, particularly bronchiolitis obliterans syndrome (BOS). New techniques with the potential to increase donor lung supply and prevent rejection continue to evolve. These developments hold promise for improved outcomes for a greater number of patients.
肺移植(LTx)是终末期肺病(ESLD)的既定治疗方法。肺移植后的存活受到感染和排斥反应的限制,尤其是闭塞性细支气管炎综合征(BOS)。有可能增加供肺供应并预防排斥反应的新技术不断发展。这些进展有望为更多患者带来更好的治疗效果。